Department of Dermatology & STD, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.
Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China.
Int J Surg Pathol. 2024 Jun;32(4):803-809. doi: 10.1177/10668969231195032. Epub 2023 Sep 18.
Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related adverse event induced by camrelizumab (SHR-1210). Very rare cases have been reported in oral tissues, especially the oral mucosa. We reported a 67-year-old male with Grade 3 RCCEP. Multiple dome-shaped and bright red papules were first observed in the oral mucosa, which gradually developed on his lip, face, scalp, neck, foot, calf, abdomen and groin. The patient's symptoms gradually improved at 4 weeks after SHR-1210 discontinuation and were mostly relieved at 7 weeks after discontinuation. Our findings revealed that oral examination should be performed regularly during SHR-1210 treatment.
皮肤毛细血管内皮细胞反应性增生（RCCEP）是卡瑞利珠单抗（SHR-1210）引起的最常见的免疫相关不良反应。口腔组织中极为罕见，特别是口腔黏膜。我们报告了一例 67 岁男性患者，其 RCCEP 为 3 级。首先在口腔黏膜中观察到多个圆顶状和鲜红色丘疹，随后逐渐在唇、面、头皮、颈部、足部、小腿、腹部和腹股沟发展。SHR-1210 停药 4 周后，患者症状逐渐改善，停药 7 周后基本缓解。我们的发现表明，在 SHR-1210 治疗期间应定期进行口腔检查。
